3-Methyl-4-hydroxyphenylglycol (MHPG) is a significant metabolite produced from the breakdown of norepinephrine, a key neurotransmitter in the central nervous system. It is formed when catechol-O-methyltransferase (COMT) metabolizes norepinephrine, and is further broken down into vanillylmandelic acid (VMA).
The levels of MHPG in plasma, urine, and cerebrospinal fluid (CSF) serve as potential biomarkers for various neurological and psychiatric conditions associated with norepinephrine dysregulation.
Elevated MHPG levels may indicate increased norepinephrine turnover, linked to stress, anxiety, mania, and hypertension.
Conversely, decreased levels might be observed in conditions such as Parkinson's disease and certain types of encephalopathy.
While the clinical utility of MHPG as a biomarker is debated due to variability influenced by diet, medications, and testing methods, its measurement remains crucial in understanding and managing disorders related to catecholamine metabolism.
3-Methyl-4-hydroxyphenylglycol (MHPG) is a metabolite formed from the breakdown of norepinephrine, a key neurotransmitter in the central nervous system. It is produced when the enzyme catechol-O-methyltransferase (COMT) metabolizes norepinephrine, and MHPG itself is further metabolized to vanillylmandelic acid (VMA), another norepinephrine metabolite.
As an O-methylated metabolite of norepinephrine, MHPG is a byproduct of the central nervous system's norepinephrine metabolism.
Levels of MHPG in plasma, urine, and cerebrospinal fluid (CSF) have been studied as potential biomarkers for various neurological and psychiatric conditions related to norepinephrine dysregulation. [6.]
Elevated MHPG levels may indicate increased norepinephrine turnover and have been associated with conditions like stress, anxiety, mania, and hypertension. [1., 4., 6.]
In contrast, decreased levels may be seen in conditions such as Parkinson's disease and certain types of encephalopathy. [3., 5., 12.]
However, the clinical utility of MHPG as a biomarker remains controversial due to variability in its levels and the influence of various factors such as diet, medications, and analytical methods.
Norepinephrine is synthesized from the amino acid tyrosine through a series of enzymatic reactions. The enzyme tyrosine hydroxylase converts tyrosine to L-DOPA, which is then decarboxylated by aromatic L-amino acid decarboxylase to form dopamine.
Dopamine β-hydroxylase then converts dopamine to norepinephrine. MHPG is produced from norepinephrine through the action of monoamine oxidase (MAO) and aldehyde dehydrogenase.
Several factors can influence MHPG levels, including:
Blood, urine, and cerebrospinal fluid (CSF) are commonly used samples for MHPG analysis. Factors such as sample handling, storage conditions, and pre-analytical processing can significantly impact MHPG levels.
It is important to consult with the ordering provider, as specialized preparation instructions, including avoidance or alteration of certain foods or medications, may be required prior to sample collection.
Optimal levels of MHPG should fall within a range, although patients diagnosed with conditions such as anxiety disorders have been found to have higher levels of MHPG in saliva; therefore, levels toward the lower end of the recommended range may be considered optimal. [13.]
For reference, one company reports the following reference ranges for MHPG in urine: 0.02-0.22 mmol/mol creatinine [11.]
It is essential to consult with the laboratory company for their recommended range, as well as consulting with a healthcare professional, especially if symptoms including anxiety, depression, mania, hypertension or other symptoms are present.
Elevated levels of MHPG indicate elevated norepinephrine levels, which may have clinical implications including hypertension, anxiety, or mania. [1., 4., 6., 13.]
Low levels of MHPG may not have clinical significance. However, low levels have been found in cases of Parkinson’s disease and encephalopathy, so in these settings low levels of MHPG may warrant further assessment.
Additionally, because norepinephrine has been well-correlated with depression, a finding of low levels of MHPG with an individual suffering from depression may also have clinical relevance. [8.]
In addition to MHPG, several other biomarkers are closely related to catecholamine metabolism and have been studied in various clinical contexts.
Understanding the relationship between MHPG and these related biomarkers can provide a more comprehensive picture of the underlying pathophysiology and aid in the interpretation of MHPG levels.
Catecholamines including dopamine, norepinephrine, and epinephrine are the precursors of MHPG and play crucial roles in various physiological processes.
Measuring catecholamine levels can provide insights into the overall activity of the sympathetic nervous system and help in the diagnosis of conditions such as pheochromocytoma and neuroblastoma.
VMA and HVA are the major metabolites of norepinephrine and dopamine, respectively. These biomarkers have been used in the diagnosis and monitoring of neuroblastoma, a type of childhood cancer.
VMA and HVA levels can provide information about the overall catecholamine metabolism and help in the assessment of sympathetic nervous system function.
5-HIAA is the main metabolite of serotonin, a neurotransmitter that plays a role in mood regulation and sleep.
Elevated levels of 5-HIAA have been associated with carcinoid tumors, a type of neuroendocrine tumor. Measuring 5-HIAA levels can help in the diagnosis and monitoring of these tumors.
Assessing an individual’s genetic capacity for the MAO enzyme may be prudent, especially in situations where elevated levels of MHPG are seen.
Click here to compare testing options and order testing for MHPG.
[1.] Bremner JD, Krystal JH, Southwick SM, Charney DS. Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. Synapse. 1996 May;23(1):39-51. doi: 10.1002/(SICI)1098-2396(199605)23:1<39::AID-SYN5>3.0.CO;2-I. PMID: 8723134.
[2.] Dorszewska J, Prendecki M, Oczkowska A, Rozycka A, Lianeri M, Kozubski W. Polymorphism of the COMT, MAO, DAT, NET and 5-HTT Genes, and Biogenic Amines in Parkinson's Disease. Curr Genomics. 2013 Dec;14(8):518-33. doi: 10.2174/1389202914666131210210241. PMID: 24532984; PMCID: PMC3924247.
[3.] Emamzadeh FN, Surguchov A. Parkinson's Disease: Biomarkers, Treatment, and Risk Factors. Front Neurosci. 2018 Aug 30;12:612. doi: 10.3389/fnins.2018.00612. PMID: 30214392; PMCID: PMC6125353.
[4.] Gurguis GNM, Uhde TW. The relationship between plasma MHPG and NE: employing regression models in estimating centrally derived MHPG and peripheral NE turnover rate in panic disorder. Journal of Psychiatric Research. 1998;32(1):11-17. doi:https://doi.org/10.1016/s0022-3956(97)00036-8
[5.] Horikoshi S, Miura I, Kunii Y, Asano S, Kanno-Nozaki K, Mashiko H, Yabe H. Hashimoto encephalopathy with high plasma monoamine metabolite levels: a case report. Neuropsychiatr Dis Treat. 2017 Apr 7;13:1043-1045. doi: 10.2147/NDT.S131356. PMID: 28435274; PMCID: PMC5391161.
[6.] Jimerson DC, Nurnberger JI Jr, Post RM, Gershon ES, Kopin IJ. Plasma MHPG in rapid cyclers and healthy twins. Arch Gen Psychiatry. 1981 Nov;38(11):1287-90. doi: 10.1001/archpsyc.1981.01780360103012. PMID: 7197905.
[7.] MedChem Express. Accessed May 26, 2024. https://www.medchemexpress.com/3-methoxy-4-hydroxyphenylglycol.html
[8.] Moret C, Briley M. The importance of norepinephrine in depression. Neuropsychiatr Dis Treat. 2011;7(Suppl 1):9-13. doi: 10.2147/NDT.S19619. Epub 2011 May 31. PMID: 21750623; PMCID: PMC3131098.
[9.] Neurotransmitter - an overview | ScienceDirect Topics. Sciencedirect.com. Published 2015. https://www.sciencedirect.com/topics/medicine-and-dentistry/neurotransmitter
[10.] P. aeruginosa Metabolome Database: 3-methoxy-4-hydroxyphenylglycol (PAMDB120410). Umaryland.edu. Published 2018. Accessed May 27, 2024. http://qpmf.rx.umaryland.edu/PAMDB?MetID=PAMDB120410
[11.] Rupa Health. 1.Metabolomix+ Sample Report.pdf. Google Docs. Accessed May 27, 2024. https://drive.google.com/file/d/1D4EkJRnZBoLyiqJnurUOsKXJG2ya6q55/view
[12.] Wichit P, Thanprasertsuk S, Phokaewvarangkul O, Bhidayasiri R, Bongsebandhu-Phubhakdi S. Monoamine Levels and Parkinson's Disease Progression: Evidence From a High-Performance Liquid Chromatography Study. Front Neurosci. 2021 Jul 29;15:605887. doi: 10.3389/fnins.2021.605887. PMID: 34393700; PMCID: PMC8358115.
[13.] Yamada S, Yamauchi K, Yajima J, Hisadomi S, Maeda H, Toyomasu K, Tanaka M. Saliva level of free 3-methoxy-4-hydroxyphenylglycol (MHPG) as a biological index of anxiety disorders. Psychiatry Res. 2000 Apr 10;93(3):217-23. doi: 10.1016/s0165-1781(00)00118-9. PMID: 10760380.